School of Medicine


Showing 21-39 of 39 Results

  • Shuchi Anand

    Shuchi Anand

    Assistant Professor of Medicine (Nephrology) at the Stanford University Medical Center

    Current Research and Scholarly Interests Management of CKD and ESRD in low-resource settings
    Tubulointerstitial disease
    Chronic kidney disease of unknown etiology
    ESRD and physical activity
    ESRD and vitamin D deficiency

  • Jason Andrews

    Jason Andrews

    Assistant Professor of Medicine (Infectious Diseases) and, by courtesy, of Health Research and Policy (Epidemiology)

    Current Research and Scholarly Interests Our laboratory aims to develop and test innovative approaches to the diagnosis, treatment and control of infectious diseases in resource-limited settings. We draw upon multiple fields including mathematical modeling, microbial genetics, field epidemiology, statistical inference and biodesign to work on challenging problems in infectious diseases, with an emphasis on tuberculosis and tropical diseases.

  • Justin P. Annes M.D., Ph.D.

    Justin P. Annes M.D., Ph.D.

    Associate Professor of Medicine (Endocrinology)

    Current Research and Scholarly Interests The ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders

    DIABETES
    The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.

    (1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual?s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.

    (2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.

    HEREDIATY PARAGAGLIOMA SYNDROME
    The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.

    As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.

  • Sally Arai

    Sally Arai

    Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center

    Current Research and Scholarly Interests Research interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.

  • Danit Ariel

    Danit Ariel

    Clinical Assistant Professor, Medicine - Endocrinology, Gerontology, & Metabolism

    Bio Danit Ariel, MD MS, is double board certified in Internal Medicine and Endocrinology. Dr. Ariel graduated from UC Davis School of Medicine. She then completed a residency in Internal Medicine at Stanford and a fellowship and post-doctorate in Endocrinology and Metabolism at Stanford before joining the faculty at Stanford.

    Dr. Ariel practices general endocrinology, with a special interest in thyroid disorders, menopause, LGBTQ+ health, and transgender medicine amongst others.

    She believes in practicing compassionate care: in listening to her patients? concerns, respecting their values, communicating well, and providing an evidence-based approach to help guide individualized treatment plans. She is deeply committed to utilizing her expertise in the field of endocrinology to optimize her patients? health and well-being.

    Dr. Ariel is passionate about medical education and teaching, and serves on the teaching faculty in the Stanford University School of Medicine. She completed an honors certificate in medical education from Stanford. She is the Founding Director of the Student Guidance Program for medical students. Finally, within the division of Endocrinology, she is the Director of Faculty Wellness.

    Appointments with with Dr. Ariel are available in the Hoover Pavilion on 211 Quarry Road.

  • Steven Artandi

    Steven Artandi

    Director, Stanford Cancer Institute, Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry

    Current Research and Scholarly Interests Telomeres are nucleoprotein complexes that protect chromosome ends and shorten with cell division and aging. We are interested in how telomere shortening influences cancer, stem cell function, aging and human disease. Telomerase is a reverse transcriptase that synthesizes telomere repeats and is expressed in stem cells and in cancer. We have found that telomerase also regulates stem cells and we are pursuing the function of telomerase through diverse genetic and biochemical approaches.

  • Steven Asch

    Steven Asch

    Professor of Medicine (Primary Care and Population Health)

    Current Research and Scholarly Interests Describe your current research interest and activities

  • Euan A. Ashley

    Euan A. Ashley

    Associate Dean, School of Medicine, Professor of Medicine (Cardiovascular), of Genetics, of Biomedical Data Science and, by courtesy, of Pathology at the Stanford University Medical Center

    Current Research and Scholarly Interests The Ashley lab is focused on precision medicine. We develop methods for the interpretation of whole genome sequencing data to improve the diagnosis of genetic disease and to personalize the practice of medicine. At the wet bench, we take advantage of cell systems, transgenic models and microsurgical models of disease to prove causality in biological pathways and find targets for therapeutic development.

  • Rebecca Aslakson

    Rebecca Aslakson

    Associate Professor of Medicine (Primary Care and Population Health) and of Anesthesiology, Perioperative and Pain Medicine at the Stanford University Medical Center

    Bio Dr. Rebecca A. Aslakson is an Associate Professor at Stanford University with appointments in both the Department of Primary Care & Population Health in the Palliative Care Section and the Department of Anesthesiology, Perioperative and Pain Medicine where she serves as Division Chief of Critical Care Anesthesia. With a Summa Cum Laude B.A. from Washington University in St. Louis, an MD from Harvard Medical School?MIT, and an MSci degree with Distinction from the University of Ulster in Northern Ireland, Dr. Aslakson completed anesthesia residency at Massachusetts General Hospital and surgical critical care fellowship at The Johns Hopkins Hospital, where she was on faculty from 2008-2017. In 2013, Dr. Aslakson obtained her PhD in Clinical Investigations from The Johns Hopkins Bloomberg School of Public Health with her dissertation concerning integration of palliative care in intensive care units. Triple boarded in anesthesia, surgical critical care, and palliative medicine, Dr. Aslakson is an active researcher and clinician; her goal is to improve delivery of effective and equitable palliative care, particularly to perioperative and critically ill populations. She has published over 80 peer-reviewed papers, invited editorials, and book chapters and received competitive funding from funders such as AHRQ, PCORI, the Foundation for Anesthesia Education and Research, and the National Palliative Care Research Society. Dr. Aslakson serves on national committees for professional societies including the American Academy of Hospice and Palliative Medicine (AAHPM), the American Society of Anesthesiologists (ASA), and the Society of Critical Care Medicine (SCCM). Dr. Aslakson has received national awards including the 2015 AAHPM Early Career Investigator Award and the 2014 ASA Presidential Scholar Award. Dr. Aslakson clinically attends at the Stanford University Medical Center in the M4 and E2 Intensive Care Units and on the inpatient palliative care clinical service. She lives in Palo Alto, CA with her husband and two sons.

  • Themistocles (Tim) Assimes

    Themistocles (Tim) Assimes

    Associate Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Health Research and Policy (Epidemiology)

    Current Research and Scholarly Interests Genetic Epidemiology, Genetic Determinants of Complex Traits related to Cardiovasular Medicine, Coronary Artery Disease related pathway analyses and integrative genomics, Mendelian randomization studies, risk prediction for major adverse cardiovascular events, cardiovascular medicine related pharmacogenomics, ethnic differences in the determinants of Insulin Mediated Glucose Uptake, pharmacoepidemiology of cardiovascular drugs & outcomes

  • Mehrdad Ayati

    Mehrdad Ayati

    Adjunct Clinical Assistant Professor, Medicine - Primary Care and Population Health

    Bio Dr. Ayati completed his residency at UC Davis and his fellowship at Stanford University. During his residency at UC Davis, Dr. Ayati received the Award of Excellence in Clinical Teaching. Dr. Ayati worked at hospitals such as Lodi Memorial Hospital in Lodi, California, and as an Emergency Medicine Attending at Veteran Affairs in Palo Alto, California. Dr. Ayati worked as a Stanford Medical Director at Los Altos and Palo Alto Sub acute and Rehabilitation centers. Dr. Ayati has a broad spectrum of practice and knowledge of general medicine and primary care in various settings, from office to Emergency room and acute and Sub-acute cares. Dr. Ayati?s main areas of research and clinical focus are in the physiology of aging and on finding practical and yet innovative ways of addressing the wellbeing and needs of the population in any age category. Dr. Ayati is an advocate of his patient?s physical and mental health at any age in addition to disease management and prevention. Dr. Ayati is currently the Editor in Chief of the journal of General Medicine, Open Access. Dr. Ayati is the author of ?Paths to Healthy Aging?. Dr. Ayati is also a guest educational speaker on several radio stations such as National Public Radio (NPR) and San Francisco?s KQED and international and national conferences.

    Dr. Ayati strives to provide reliable information, effective strategies, and simple guidelines for patients of all ages to avoid or manage chronic diseases and to have a significantly better quality of life.

Footer Links:

Stanford Medicine Resources: